GGrantIndex
← Leaderboards

Neera Tewari-Singh

University Of Colorado Denver

$3,731,189
Attributed
$5,430,475
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY201725
$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,430,475 · 5

By mechanism

R01$2,933,326 · 2
U01$1,422,295 · 1
R21$1,074,854 · 2

Top collaborators

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Toxic Effect

Research focus

Toxic EffectTissuesPathway InteractionsInflammationAcuteInjuryOrganEffective TherapyBiological MarkersResponseVesicantsIn VivoPublishingTreatment StrategyInflammatoryNew Therapeutic TargetTherapeutic TargetChemical AgentsCytokineMustardDesignNecrosisTherapeutic InterventionInflammatory Response

Grant awards (15)

Mast Cell Activation as a Common Mechanism of Pulmonary Toxicity by Chemical Threat Agents$1,395,741
R01 · FY2025 · ES
Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models$453,286
R01 · FY2025 · EY · contact PI
Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models$156,998
R01 · FY2025 · EY · contact PI
Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models$460,271
R01 · FY2024 · EY · contact PI
Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models$467,030
R01 · FY2023 · EY · contact PI
Treatment strategies for ocular toxicity from chloropicrin$156,991
R21 · FY2023 · EY · contact PI
Treatment strategies for ocular toxicity from chloropicrin$234,750
R21 · FY2022 · EY · contact PI
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure$469,390
U01 · FY2021 · AR · contact PI
Treatment strategies for ocular toxicity from chloropicrin$195,625
R21 · FY2021 · EY · contact PI
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure$474,397
U01 · FY2020 · AR · contact PI
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure$478,508
U01 · FY2019 · AR · contact PI
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets$240,736
R21 · FY2018 · AR · contact PI
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets$28,775
R21 · FY2018 · AR · contact PI
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets$4,152
R21 · FY2018 · AR · contact PI
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets$213,825
R21 · FY2017 · AR · contact PI